Clinical trial
Five Year Study to Track Use of DecisionDX-Melanoma Test in Patients With…
NCT02355587 · Castle Biosciences Incorporated, Industry · Terminated
Key facts
| NCT number | NCT02355587 |
|---|---|
| Title | Five Year Study to Track Use of DecisionDX-Melanoma Test in Patients With Cutaneous Melanoma and Associated Patient Outcomes |
| Official title | An Open, 5-year Registry Study to Track Clinical Application of DecisionDx-Melanoma Gene Expression Profile Assay Results and Associated Patient Outcomes |
| Acronym | EXPAND |
| Lead sponsor | Castle Biosciences Incorporated, Industry |
| Status | Terminated |
| Study type | Observational [Patient Registry] |
| Conditions | Cutaneous Melanoma |
| Enrollment | 72 |
| Start date | Mar 1, 2014 |
| Primary completion | Jul 1, 2021 |
| Completion | Jul 31, 2021 |
| First posted | Feb 4, 2015 |
| Last update posted | Oct 8, 2021 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: